0 0.000179275726066697 0.000537827178200092 0.00032867216445564 0.00164336082227803 0.00200191227441143 0.00182263654834473 0.00418310027488955
Sign Up Today X
Thanks for submitting the form.
Stockreport

Converge Bio raises $25M, backed by Bessemer and execs from Meta, OpenAI, Wiz [TechCrunch]

Alphabet Inc. - Class C Capital Stock (GOOG)  More Company Research Source: TechCrunch
Last alphabet inc. - class c capital stock earnings: 4/28 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: abc.xyz/investor
More than 200 startups are now competing to weave AI directly into research workflows, attracting growing interest from investors. Converge Bio is the latest company to ride that shift, securing new capital as competition in the AI-driven drug discovery space heats up. The Boston- and Tel Aviv–based startup, which helps pharma and biotech companies develop drugs faster using generative AI trained on molecular data, has raised a $25 million oversubscribed Series A round, led by Bessemer Venture Partners. TLV Partners and Vintage Investment Partners also joined the round, along with additional backing from unidentified executives at Meta, OpenAI, and Wiz. In practice, Converge trains generative models on DNA, RNA, and protein sequences then plugs them into pharma and biotech's workflows to speed up drug development. “The drug-development lifecycle has defined stages — from target identification and discovery to manufacturing, clinical trials, and beyond — and within each, there ar [Read more]
IMPACT SNAPSHOT EVENT TIME: GOOG
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GOOG alerts
from News Quantified
GOOG
NEWS
GOOG
Earnings
GOOG
Analyst Actions
GOOG
SEC Filings
Stockreport

Converge Bio raises $25M, backed by Bessemer and execs from Meta, OpenAI, Wiz [TechCrunch]

Alphabet Inc. - Class C Capital Stock  (GOOG) 
More Company Research Source: TechCrunch
Last alphabet inc. - class c capital stock earnings: 4/28 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: abc.xyz/investor
More than 200 startups are now competing to weave AI directly into research workflows, attracting growing interest from investors. Converge Bio is the latest company to ride that shift, securing new capital as competition in the AI-driven drug discovery space heats up. The Boston- and Tel Aviv–based startup, which helps pharma and biotech companies develop drugs faster using generative AI trained on molecular data, has raised a $25 million oversubscribed Series A round, led by Bessemer Venture Partners. TLV Partners and Vintage Investment Partners also joined the round, along with additional backing from unidentified executives at Meta, OpenAI, and Wiz. In practice, Converge trains generative models on DNA, RNA, and protein sequences then plugs them into pharma and biotech's workflows to speed up drug development. “The drug-development lifecycle has defined stages — from target identification and discovery to manufacturing, clinical trials, and beyond — and within each, there ar [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GOOG
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS